Wisconsin Hospital Becomes First to Implement New Nitric Oxide Delivery System
The hospital is using the INOmax Evolve DS system, a nitric oxide delivery device used with mechanical ventilation for critically ill patients.
The hospital is using the INOmax Evolve DS system, a nitric oxide delivery device used with mechanical ventilation for critically ill patients.
The hospital is using the INOmax Evolve DS system, a nitric oxide delivery device used with mechanical ventilation for critically ill patients.
Read MoreMallinckrodt has begun a national rollout of the INOmax Evolve DS delivery system, which is FDA-cleared to provide inhaled nitric oxide to certain neonatal ICU patients in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation.
Read MoreIdentifying and treating people with previously undiagnosed asthma or COPD led to improved respiratory symptoms, quality of life, and reduced healthcare visits in the year after diagnosis.
Read MoreHigh-dose inhaled nitric oxide (iNO) therapy may improve oxygenation and reduce the risk of ARDS-related mortality among critically ill Black patients with COVID-19, according to a first-of-its-kind study published in the American Journal of Respiratory and Critical Care Medicine.
Read MoreThe INOmax Evolve DS is Mallinckrodt’s next-generation nitric oxide delivery system that includes a primary delivery system, a monitoring system, an electronic blender, automated backup delivery, mini-cylinders, and more.
Read MoreA phase 2 study showed the treatment improved blood oxygen levels and lowered the risk of long-term sensory and motor neurologic symptoms.
Read MoreMallinckrodt Manufacturing is recalling its one-way valve, 22F x 22M, due to devices not opening properly, which prevents or reduces the flow of ventilated air or oxygen.
Read MoreThe recall was issued due to a misalignment of the check valve in the device’s manifold, which may cause the manifold to fail and interrupt therapy to neonates.
Read MoreRT magazine spoke with manufacturers of inhaled nitric oxide delivery systems about the latest market innovations in the iNO industry, specifically about the impact of cylinder-free (“tankless”) systems, plus research on its potential use to treat other cardiopulmonary diseases.
Read MoreThe US FDA has approved the third Generation Genosyl Delivery System, a tankless inhaled nitric oxide (iNO) therapy device, according to manufacturer Vero Biotech Inc.
Read MoreInhaled nitric oxide has been utilized as a pulmonary vasodilator for over 20 years and research is ongoing to uncover the usefulness of iNO in several lung diseases and disorders.Â
Read MoreMallinckrodt plc reports the submission of a 510(k) premarket notification application to the US FDA for an investigational inhaled nitric oxide delivery system for INOmax (nitric oxide) gas, for inhalation.
Read MoreHigh-dose inhaled nitric oxide led to more rapid weaning from supplemental oxygen and reduced length of hospital stay in pregnant women hospitalized with severe COVID-19 pneumonia, according to a study published in Obstetrics & Gynecology.
Read MoreResearchers assessed outcomes of INOmax inhaled nitric oxide for COVID-19 patients hospitalized with mild-to-moderate ARDS.
Read MoreClinical trial and real-world data provide evidence that inhaled nitric oxide is effective for reducing pulmonary hypertension in the perioperative setting.Â
Read MoreAt-home, self-administered high concentration inhaled nitric oxide at home to treat severe nontuberculous mycobacterial (NTM) lung disease was well tolerated with no serious adverse events.
Read MoreClaritas Pharma is developing a nitric oxide-releasing compound that could potentially be administered orally, via nasal spray, or injection, and fight viral infections like SARS-CoV-2.
Read MoreThe interhospital transport of infants with persistent pulmonary hypertension of the newborn (PPHN) being administered inhaled nitric oxide therapy requires specialized, intensive care.
Read MoreThe first patient has been enrolled in Bellerophon’s Phase 3 study of pulsed inhaled nitric oxide to treat fibrotic interstitial lung disease.
Read MoreBeyond Air Inc will initiate a clinical study of its LungFit tankless nitric oxide (NO) system for evaluation of the safety and efficacy of high concentration inhaled NO given intermittently to adults hospitalized with acute viral pneumonia, including SARS-CoV-2.
Read MoreInhaled nitric oxide has been used to treat pulmonary hypertension and ARDS for decades. Now, research is emerging on positive outcomes for critical care COVID-19 patients who have been treated with iNO.
Read MoreTwo experts on inhaled nitric oxide explain the physiological effects and properties that make iNO a potential therapeutic agent in the battle against COVID-19.
Read MoreHigh dose inhaled nitric oxide resulted in improvements in physical activity and other outcomes in patients at risk for pulmonary hypertension-associated fibrotic interstitial lung disease.
Read MoreRT Magazine’s 2020 Product Focus is available in a Digital Edition for your web browser or mobile device.
Read More